Osteonectosis of the Jawbone is a disease resulting from the temporary or permanent loss of the blood supply to the bone. Without a blood supply, the bone dies (the term "osteo" means "bone"; the term "necrosis" means "death"). When this happens, the dead bone becomes exposed to the oral environment. Exposed necrotic bone is not an uncommon complication after extractions of teeth, even in healthy patients who have never had radiation therapy or bisphphonate drug therapy. Simple cases involve only the bone immediately surrounding the extraction socket, and usually, the necrotic bone will heal over spontaneously with time.
Serious ONJ is extremely rare in dentistry, and it tends to happen only to patients who have known predisposing factors such as radiation therapy for cancers of the head and neck, chemotherapy for cancers, especially therapy including large doses of corticosteroids (prednisone and other steroids), or IV bisphosphonate drug therapy for metastasizing cancers or osteoporosis. Osteonecrosis of the jaw generally happens in susceptible patients after a dental extraction or periodontal osseous surgery. It may also happen after a fall or an auto accident in which the jawbone is broken. It can even happen under an ill fitting denture. The presence of exposed necrotic bone in the oral cavity may cause the patient pain, but surprisingly, it is often asymptomatic, because the nerve supply to the bone is confined to the periosteum, which is the thin covering over the surface of the bone, and there is none inside the bone structure itself.
There is no specific treatment for osteonecrosis of the jaw other than treatments aimed at preventing infection and controlling pain if present. More advanced cases may require conservative debridement of necrotic bone. Many cases of osteonecrosis will heal over time. Some (very few) never heal. Hyperbaric oxygen treatments can be quite helpful in the management of these cases.
Other terms for osteonecrosis are avascular necrosis, aseptic necrosis and ischemic bone necrosis. There are two named types of osteonecrosis in dentistry: Osteoradio-necrosis (radiation associated bone death), and Bisphosphonate Related OsteoNecrosis of the Jaw (BRONJ).
Osteoradio-necrosis is the name given to necrosis of a portion of the jawbone in a patient who has received extensive radiation therapy for the treatment of cancers in the head and neck. Radiation affects rapidly growing cells, and the cells in the endothelial lining of blood vessels are especially vulnerable to damage from large amounts of radiation. High doses of radiation result in a cumulative progressive endarteritis (inflammation of the inner lining of the arteries) which eventually leads to the destruction of the smaller arteries in the bone. Dense bone, like that found in the lower jaw is not especially well vascularized to begin with, and therapeutic amounts of radiation (far in excess of the radiation used to take normal diagnostic dental x-rays) reduces the blood flow further making normal healing of the bone difficult.
Patients who have had extensive cancer related radiation therapy to their head or neck should be sure to tell their dentist about this and avoid having teeth extracted. This often means doing root canals on teeth that are otherwise hopelessly decayed and non restorable. Patients who have had this type of radiation therapy should be especially careful to avoid excessive sugar intake and be meticulous about their oral hygiene.
Osteoradio-necrosis is NOT associated with diagnostic x-rays like the ones your dentist takes periodically to examine your teeth.
Q. Should Patients who are about to undergo radiation therapy for cancer of the head or neck have all their teeth extracted prior to radiation treatment to avoid the possibility osteoradio-necrosis?
When I was in the army, I was called out one night to treat a soldier with an abscess. When I saw the patient, I was appalled at the state of his teeth. His mouth was filled with nothing but rotten stumps. Now, this was the army, and I knew that no soldier would be allowed to remain in the state in which I found this man. I was ready to extract the offending stump when the soldier told me to stop and call the oral surgeon in charge of the clinic.
Upon speaking to the colonel, I was told to simply drain the abscess and the soldier would be referred for a root canal. At first I was incredulous. Why do a root canal on a rotten stump? Then he told me the history of this particular patient.
He had been diagnosed with what was believed to be an incurable cancer in his upper neck and was to undergo severe radiation treatment for it. At that time, it was policy to extract all teeth on patients undergoing this type of radiation treatment to the neck and jaws because the damage to the saliva glands would cause severe dry mouth and the natural teeth would deteriorate because of rampant decay. It was a way to avoid the situation I found this soldier in.
Unfortunately, it was believed that his cancer was incurable and the soldier in question would die before the decay would have severe consequences. Therefore the decision was made to spare him the discomfort of a full mouth extraction procedure and leave him with all his teeth.
The prognosis, however, was wrong and the soldier did not die. He went into remission after his radiation therapy. This would ordinarily be good news, but because of the dry mouth and the patient's habit of drinking massive amounts of soda, his teeth rotted away is fairly short order. No one could get him to quit his soda habit. Thus we were stuck with a patient who was doomed to a lifetime of abscesses, and teeth that could not be extracted because of the strong possibility of killing him from the resulting ONJ.
This patient eventually died because of osteoradio-necrosis of the jaw due to his dental abscesses. So in retrospect, the army should have extracted his teeth prior to the radiation therapy.
A. We know today that it is NOT ALWAYS necessary to extract teeth on patients who are about to undergo radiation to the head and neck.
Patients who receive this type of radiation treatment, as well as patients undergoing chemotherapy do have severe dry mouth, and are prone to very severe tooth decay. However whether or not their teeth become decayed depends to a great extent on the amount of sugar they consume and the oral hygiene they carry out. (See my page on tooth decay to find out why this is so. ) Today, if a patient is willing to make a commitment to excellent hygiene and promises to avoid excessive sugar, we can make a set of fluoride trays which the patient uses after brushing and flossing twice a day. This regimen generally avoids tooth decay, and the patient may keep his or her teeth for the rest of his/her life.
On the other hand, if a patient already has a lot of severe tooth decay, poor oral hygiene and a habit of eating and drinking sugary foods, then extraction of the teeth prior to radiation therapy would be advisable.
Radiation therapy was originally considered a contraindication (This means that it was considered a bad idea) for installation of dental implants. This is no longer the case. In most cases, patients benefit greatly from dental implants after radiation therapy because:
1) these patients are more likely to loose the remaining teeth due to decay from the dry mouth caused by the radiation therapy,
2) the failure of a dental implant after radiation therapy does not necessarily imply (or cause) osteoradionecrosis, and
3) strategically placed implants can restore the patient's ability to eat properly, as well as to smile and speak with confidence, both of which are essential to the patients ability to recover from their cancer.
While most dental implants placed in irradiated bone do survive for ten years or more, overall, implants in these patients still have a greater risk for failure. Once again, failure of a dental implant does not necessarily imply osteoradionecrosis, although this can certainly happen. Survival of implants is significantly influenced by the location of the implant (maxilla or mandible, anterior or posterior). In one study;
A total of 48 patients who had prior head and neck radiation had 271 dental implants placed during May 1987 to July 2008. The estimated survival at 1, 5, and 10 years was 98.9%, 89.9%, and 72.3%, respectively. Implants placed in the maxilla were more likely to fail than implants placed in the mandible. There was also a tendency for implants placed in the posterior region to fail compared with those placed in the anterior region. Conclusion: Dental implants placed in irradiated bone have a greater risk for failure. Survival is significantly influenced by the location of the implant (maxilla or mandible, anterior or posterior).
The risk of osteoradionecrosis after extractions in patients who have had high dose radiation to the head and neck area for various forms of cancer is very high. Therefore, extractions of teeth with poor prognosis should be done before radiation therapy if possible. After radiation therapy, extractions should be avoided at all costs, even to the point of performing root canal therapy on the retained roots, followed by copings (little caps).
Although data on this point is still thin, it appears that implants placed at least one month before radiation therapy are somewhat less likely to fail than those placed after radiation therapy (although in both cases, the probability of implant survival is still fairly high).
The danger of osteoradionecrosis actually increases with the passage of time after the irradiation of the bone. Therefore, there is no basis to perform extractions just because the radiation happened many years ago. This also means that the probability of implant failure increases over the years.
General dentist or specialist:
Whenever a general dentist encounters a patient with a history of radiation therapy to the head or neck and is also in need of either an extraction or implant surgery, he or she should refer the patient to a qualified oral surgeon for any surgical procedures (including implant placement) and confine his or her own involvement to the restorative needs of the patient post-op.
Bisphosphonates are therapeutic agents used to treat diseases that feature bone fragility. These diseases include osteoporosis, Paget's disease of bone, multiple myeloma and certain cancers in which metastases are a feature, especially breast cancer. Bisphosphonates inhibit osteoclast activity thus inhibiting the resorption of bone. This will make the bone more dense, but also less vascularized and less able to remodel after injuries.
Necrotic bone exposed to the oral environment for at least eight weeks in a patient that has been treated with any of the bisphosphonates is called Bisphosphonate Related OsteoNecrosis of the Jaw, or ARONJ for short. Some authorities refer to it as BON which stands for Bisphosphonate OsteoNecrosis. ARONJ can be a complication after extractions, periodontal surgery involving bone recontouring or facial trauma from any source. It can also occur spontaneously in susceptible patients. BRONJ can occur in the upper or lower jaw, however the incidence in the lower jaw is twice as high as in the upper. BRONJ may also follow less traumatic injuries such as chronic denture sores.
There is no specific treatment for Bisphosphonate Related OsteoNecrosis of the Jaw other than treatments aimed at preventing infection and controlling pain if present. More advanced cases may require conservative debridement of necrotic bone. I am unable to find any reference to patients actually dying as a direct result of BRONJ, although patients being treated with IV bisphosphonates for metastasizing cancers or multiple myeloma may die of an accumulation of the side effects of their treatment modalities which may include very serious BRONJ. In patients taking low doses of oral bisphosphonates for osteoporosis (such as Actonel, Boniva, or Fosamax), spontaneous healing is actually quite a frequent occurrence.
Most people are familiar with the names of several of the oral drugs used to treat osteoporosis, since the companies that manufacture them do a lot of advertising.
|Brand Name||Manufacturer||Generic Name|
|Actonel||Procter & Gamble Pharmaceuticals||risedronate|
|Fosamax||Merck & Co.||alendronate|
|Fosamax Plus D||Merck & Co.||alendronate|
|Didronel||Procter & Gamble Pharmaceuticals||etidronate|
Patients taking oral bisphosphonates such as the ones listed above, have a very low risk of developing ARONJ. These patients seem to have less severe manifestations of necrosis which respond more readily to stage specific treatment regimens. Dentists should inform patients that they have a small chance of contracting osteonecrosis, however dentoalveolar surgery does not appear to be contraindicated in this group. The actual incidence of BRONJ in the total population of patients who take oral bisphosphonates is approximately 0.7 cases per 100,000 patients per year. The risk of BRONJ is especially low if the patient has been taking the bisphosphonate for less than three years and has no other complicating factors. These complicating factors include:
Patient over 65 years old
Concurrent steroid use
Poor oral hygiene
Therapeutic head and neck radiation
Concurrent administration of other chemotherapeutic agents
The benefits of the current antiresorptive drugs far outweigh the risks of ARONJ, and patients should not be deterred from taking them if they are indicated, and prescribed by a physician. The benefits from antiresorptive drugs include the following:
They reduce the incidence of spine and hip fractures by 50%
They reduce mortality from bone fracture
They may inhibit bone metastases from breast cancer
Better quality of life for those at risk from osteoporosis
They improve pain management from metastatic tumors
Question: Does the risk for BRONJ decrease if the patient stops taking the oral bisphosphonate for several months before having their extraction?
Answer: There is no hard data proving that there is a benefit to halting oral bisphosphonate medication, even for several months prior to the surgical procedure. Evidence suggests that the drug remains in the bony structure more or less permanently. The half life of bisphosphonates in bone is about 10 years. Even so, drug holidays are still recommended for patients who have been taking their drug for over three years.
The rule of thumb seems to be that no delay in surgery is necessary for patients who have been taking oral bisphosphonates for less than three years unless they have one or more of the above complicating factors. If the patient has been taking bisphosphonates for more than three years or has complicating factors, a three month drug holiday is advised prior to surgery with the holiday extending until bony healing is complete (usually about three months post-op). Click here for the reference.
Question: Does the length of time a patient has been taking an oral bisphosphonate affect the probability that the patient will contract BRONJ?
Answer: Yes! The general consensus is that the probability of contracting bisphosphonate related osteonecrosis of the jaw as a result of dental osseous surgeries during the first three years of oral drug therapy is substantially less than for those patients who have been taking the drug for more than three years. Patients and dentists should strive to produce a state of oral health during the first three years of bisphosphonate therapy to reduce the likelihood of BRONJ later.
Question: Is a patient taking oral bisphosphonates likely to develop BRONJ after implant placement?
Answer: Implants have been known to fail in patients taking oral bisphosphonates, however it is not altogether clear if the failure of the implants in question were a result of the oral bisphosphonate regimen, or were associated with some other patient or technique related factor. Studies of patients on oral bisphosphonates receiving implants indicate a very low risk of either implant loss or BRONJ following implant placement. The general consensus now is that oral bisphosphonates are NOT a contraindication for dental implants, even if the patient has been taking them for a very prolonged period.
While patients taking oral bisphosphonates show a very low risk of BRONJ, patients taking IV (injection) bisphosphonates are at significant risk of developing BRONJ after extractions or other surgical interventions involving the manipulation of bone (incidence is 0.8-12%). IV bisphosphonates are generally used as part of a chemotherapeutic regimen for the treatment of cancer. The most commonly used IV bisphosphonates are:
|Brand Name||Manufacturer||Generic Name|
Any patient who has been treated with IV bisphosphonates should follow these guidelines:
Avoid extractions unless the teeth are very mobile.
Choose root canals rather than extractions whenever possible.
Have extremely good oral hygiene and regular dental care.
Be especially careful to keep your dentures in good repair to avoid chronic sore spots. Patients are advised to have relines every 2 years and get new dentures every five to seven years. (Click here to see why.)
Before the prescription of bisphosphonates for bone disease the patient should be made dentally fit so that the need for subsequent dental extractions is minimized.
Exposed/necrotic bone in patients who are asymptomatic and have no evidence of infection.
Treatment of stage 1: These patients benefit from the use of oral antimicrobial rinses, such as chlorhexidine 0.12%. No surgical treatment is indicated. Patients who present with Stage 1 disease have done well with this type of conservative treatment.
Exposed/necrotic bone in patients with pain and clinical evidence of infection.
Treatment of stage 2: These patients benefit from the use of oral antimicrobial rinses (chlorhexidine) in combination with antibiotic therapy. Penicillin is the drug of choice, with clindamycin used if the patient is allergic to penicillin.
Exposed/necrotic bone in patients with pain, infection, and one or more of the following: pathologic fracture, extra-oral fistula, or osteolysis extending to the inferior border.
Treatment of stage 3: These patients typically have pain that impacts the quality of life. Surgical debridement/resection in combination with antibacterial mouth rinses (chlorhexidine) and antibiotic therapy may offer long-term palliation with resolution of acute infection and pain.